A promising CAR-T therapy currently in clinical evaluation is the “pan-ErbB-targeted T4 immunotherapy,” which is being tested in a phase I/II clinical trial for HNSCC [80]. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.